NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

It is well known there has been not much improvement in OS for SOC GBM patients over many many years, and the OS for SOC GBM patients has been in a tight range, again evidenced by numerous completed trials so it's rational and reasonable for our trial to use the past SOC OS data as a compare as in one option. Of course other options should still stand, such as comparing the earlier and the later vaccinated patients in the trial, etc.

Before unblinding, no one has 100% confidence that the trial will be a slam dunk; otherwise Linda would have committed a "crime" by giving away many tens of millions of shares cheaply. So we only have this chance, and we should not ruin it simply because of not being conservative enough.

The point is nobody really knows how successful the trial will be before unblinding. As a result, we should exercise caution.

[As known I has only one post a day so sorry for no reply/further post today.]